Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism

FASEB Journal

Volumn 21, Issue 14, 2007, Pages 3877-3884

  Levy, Bruce D ^a   Lukacs, Nicholas W ^b   Berlin, Aaron A ^b   Schmidt, Birgitta ^a   Guilford, William J ^c   Serhan, Charles N ^a   Parkinson, John F ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c BAYER AG   (Germany)

^d BAYER CORPORATION   (United States)

Author keywords

Leukocytes; Lipid mediators; Resolution

Indexed keywords

16 (4 FLUOROPHENOXY) 3 OXA 5,6,15 TRIHYDROXY 7,9,13 HEXADECATRIEN 11 YNOIC ACID; ALLERGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LIPOXIN A; METHYL 16 (4 FLUOROPHENOXY) 5,6,15 TRIHYDROXY 7,9,11,13 HEXADECATETRAENOIC ACID; MONTELUKAST; OVALBUMIN; UNCLASSIFIED DRUG; ZK 994; 16 (4 FLUOROPHENOXY) 3 OXA 5,6,15 TRIHYDROXY 7,9,11,13 HEXADECATETRAENOIC ACID; 16-(4-FLUOROPHENOXY)-3-OXA-5,6,15-TRIHYDROXY-7,9,11,13-HEXADECATETRAENOIC ACID; ACETIC ACID DERIVATIVE; ALLERGEN CRA, COCKROACH; ANTIASTHMATIC AGENT; DIPHENYL ETHER DERIVATIVE; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXIN; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVATIVE;

AEROSOL; ALLERGIC REACTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EOSINOPHIL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; RESPIRATORY TRACT ALLERGY; STRUCTURE ACTIVITY RELATION;

BLATTARIA; MUS;

ACETATES; ALLERGENS; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; LEUKOTRIENE ANTAGONISTS; LIPOXINS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; OVALBUMIN; PHENYL ETHERS; QUINOLINES; RECEPTORS, LEUKOTRIENE; RESPIRATORY HYPERSENSITIVITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36849087311     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-8653com     Document Type: Article

References (34)

1. Barnes, P. J. (2004) New drugs for asthma. Nat. Rev. Drug Discov. 3, 831-844
2. Wenzel, S. E., and Covar, R. (2006) Update in asthma 2005. Am. J. Respir. Crit. Care Med. 173, 698-706
3. Serhan, C. N., and Savill, J. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197
4. Gronert, K., Martinsson-Niskanen, T., Ravasi, S., Chiang, N., and Serhan, C. N. (2001) Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am. J. Pathol. 158, 3-9
5. Clish, C. B., Levy, B. D., Chiang, N., Tai, H. H., and Serhan, C. N. (2000) Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J. Biol. Chem. 275, 25372-25380
6. Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34, 14609-14615
7. Bandeira-Melo, C., Bozza, P. T., Diaz, B. L., Cordeiro, R. S., Jose, P. J., Martins, M. A., and Serhan, C. N. (2000) Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J. Immunol. 164, 2267-2271
8. Levy, B. D., De Sanctis, G. T., Devchand, P. R., Kim, E., Ackerman, K., Schmidt, B. A., Szczeklik, W., Drazen, J. M., and Serhan, C. N. (2002) Multi-pronged inhibition of airway hyperresponsiveness and inflammation by lipoxin A(4). Nat. Med. 8, 1018-1023
9. Fukunaga, K., Kohli, P., Bonnans, C., Fredenburgh, L. E., and Levy, B. D. (2005) Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174, 5033-5039
10. Hashimoto, A., Murakami, Y., Kitasato, H., Hayashi, I., and Endo, H. (2007) Glucocorticoids co-interact with lipoxin A4 via lipoxin A4 receptor (ALX) up-regulation. Biomed. Pharmacother. 61, 81-85
11. Perretti, M., Chiang, N., La, M., Fierro, I. M., Marullo, S., Getting, S. J., Solito, E., and Serhan, C. N. (2002) Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296-1302
12. Petasis, N. A., Akritopoulou-Zanze, I., Fokin, V. V., Bernasconi, G., Keledjian, R., Yang, R., Uddin, J., Nagulapalli, K. C., and Serhan, C. N. (2005) Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 73, 301-321
13. Guilford, W. J., Bauman, J. G., Skuballa, W., Bauer, S., Wei, G. P., Davey, D., Schaefer, C., Mallari, C., Terkelsen, J., Tseng, J. L., et al. (2004) Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J. Med. Chem. 47, 2157-2165
14. Fiorucci, S., Wallace, J. L., Mencarelli, A., Distrutti, E., Rizzo, G., Farneti, S., Morelli, A., Tseng, J. L., Suramanyam, B., Guilford, W. J., and Parkinson, J. F. (2004) A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. U. S. A. 101, 15736-15741
15. Guilford, W. J., and Parkinson, J. F. (2005) Second-generation beta-oxidation resistant 3-oxa-lipoxin A4 analogs. Prostaglandins Leukot. Essent. Fatty Acids 73, 245-250
16. Berlin, A. A., and Lukacs, N. W. (2005) Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am. J. Respir. Crit. Care Med. 171, 35-39
17. Busse, W. W., and Lemanske, R. F., Jr. (2001) Asthma. N. Engl. J. Med. 344, 350-362
18. Campbell, E. M., Charo, I. F., Kunkel, S. L., Strieter, R. M., Boring, L., Gosling, J., and Lukacs, N. W. (1999) Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/-mice: the role of mast cells. J. Immunol. 163, 2160-2167
19. Dahlen, S. E., Hedqvist, P., Hammarstrom, S., and Samuelsson, B. (1980) Leukotrienes are potent constrictors of human bronchi. Nature 288, 484-486
20. Henderson, W. R., Jr., Chiang, G. K., Tien, Y. T., and Chi, E. Y. (2006) Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am. J. Respir. Crit. Care Med. 173, 718-728
21. Taube, C., Dakhama, A., and Gelfand, E. W. (2004) Insights into the pathogenesis of asthma utilizing murine models. Int. Arch. Allergy Immunol. 135, 173-186
22. Bonnans, C., Vachier, I., Chavis, C., Godard, P., Bousquet, J., and Chanez, P. (2002) Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med. 165, 1531-1535
23. Machado, F. S., Johndrow, J. E., Esper, L., Dias, A., Bafica, A., Serhan, C. N., and Aliberti, J. (2006) Anti-inflammatory actions of lipoxin A(4) and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12, 330-334
24. Ariel, A., Chiang, N., Arita, M., Petasis, N. A., and Serhan, C. N. (2003) Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J. Immunol. 170, 6266-6272
25. Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., and Serhan, C. N. (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345-4355
26. Li, B. Q., Wetzel, M. A., Mikovits, J. A., Henderson, E. E., Rogers, T. J., Gong, W., Le, Y., Ruscetti, F. W., and Wang, J. M. (2001) The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1. Blood 97, 2941-2947
27. Deng, X., Ueda, H., Su, S. B., Gong, W., Dunlop, N. M., Gao, J. L., Murphy, P. M., and Wang, J. M. (1999) A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 94, 1165-1173
28. Smit, J. J., and Lukacs, N. W. (2006) A closer look at chemokines and their role in asthmatic responses. Eur. J. Pharmacol. 533, 277-288
29. Bonnans, C., Fukunaga, K., Levy, M. A., and Levy, B. D. (2006) Lipoxin A4 regulates bronchial epithelial cell responses to acid injury. Am. J. Pathol. 168, 1064-1072
30. Svensson, C. I., Zattoni, M., and Serhan, C. N. (2007) Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J. Exp. Med. 204, 245-252
31. Lee, T. H., Crea, A. E., Gant, V., Spur, B. W., Marron, B. E., Nicolaou, K. C., Reardon, E., Brezinski, M., and Serhan, C. N. (1990) Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am. Rev. Respir. Dis. 141, 1453-1458
32. Levy, B. D., Bonnans, C., Silverman, E. S., Palmer, L. J., Marigowda, G., and Israel, E. (2005) Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172, 824-830
33. Sanak, M., Levy, B. D., Clish, C. B., Chiang, N., Gronert, K., Mastalerz, L., Serhan, C. N., and Szczeklik, A. (2000) Aspirintolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16, 44-49
34. Christie, P. E., Spur, B. W., and Lee, T. H. (1992) The effects of lipoxin A4 on airway responses in asthmatic subjects. Am. Rev. Respir. Dis. 145, 1281-1284